2024
An emerging antibacterial nanovaccine for enhanced chemotherapy by selectively eliminating tumor-colonizing bacteria
Chen L, Kang Z, Shen J, Zhao R, Miao Y, Zhang L, Zheng Z, Zhang Z, Liu N, Wang C, Fang H, Zhou J, Wang Y, Liu Z, Yang Y, Chen Q. An emerging antibacterial nanovaccine for enhanced chemotherapy by selectively eliminating tumor-colonizing bacteria. Science Bulletin 2024, 69: 2565-2579. PMID: 38918142, DOI: 10.1016/j.scib.2024.06.016.Peer-Reviewed Original ResearchConceptsF. nucleatumColorectal cancerEffective antigen presentationEnhance chemotherapy efficacyT cell activationReduce cancer metastasisPoor treatment outcomesIncreased cancer cell growthCancer cell growthOral anaerobesDendritic cellsFusobacterium nucleatumChemotherapy efficacyAntitumor effectAntigen presentationBiomimetic nanovaccinesEnhanced chemotherapyNanovaccineAlum adjuvantCpG oligonucleotidesTreatment outcomesImmune responseImmune progressionTherapeutic effectVaccine effectiveness
2023
A coordinative dendrimer-based nanovaccine for cancer treatment
Cao Z, Ren L, Niu L, Zhao R, Liu N, Zhuang Q, Pan F, Liu Z, Cheng Y, Yang Y, Chen Q. A coordinative dendrimer-based nanovaccine for cancer treatment. Matter 2023, 6: 3574-3597. DOI: 10.1016/j.matt.2023.08.001.Peer-Reviewed Original ResearchCancer vaccinesCancer immunotherapyDendritic cellsField of cancer immunotherapyTumor-specific immune responsesEffective cancer immunotherapyAnti-PD-L1Efficient antigen cross-presentationAntigen cross-presentationCGAS-STING pathwayCross-presentationImmune responseCancer cellsTherapeutic effectCancer treatmentCancerCGAS-STINGImmunotherapyVaccinePeptide carrierCellsNanovaccineNeoantigensPeptidePatients